[S02DA03, antipyrine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Antipyrine.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Guanfacine.]
[J01GA01, streptomycin, Guanfacine may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA27, fingolimod, Guanfacine may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Guanfacine.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01CG01, sulbactam, Guanfacine may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, Sulfadiazine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01EC01, sulfamethoxazole, Sulfamethoxazole may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M01AB02, sulindac, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Sulindac.]
[N05AL01, sulpiride, The risk or severity of adverse effects can be increased when Sulpiride is combined with Guanfacine.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Guanfacine is combined with Sulthiame.]
[M01AX04, apazone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Azapropazone.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Guanfacine.]
[R03CC03, terbutaline, Terbutaline may decrease the antihypertensive activities of Guanfacine.]
[B01AE07, dabigatran etexilate, Guanfacine may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Guanfacine.]
[L04AX02, thalidomide, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, Theobromine may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[A11DA01, thiamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Thiamine.]
[R06AD03, thiethylperazine, The risk or severity of adverse effects can be increased when Thiethylperazine is combined with Guanfacine.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Guanfacine.]
[N05AB08, thioproperazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Thioproperazine.]
[N05AC02, thioridazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Guanfacine is combined with Thiothixene.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Guanfacine.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tiapride.]
[B01AC05, ticlopidine, Ticlopidine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tilidine.]
[S01ED01, timolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Timolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[S01AA12, tobramycin, Guanfacine may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, Tolazamide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M02AX02, tolazoline, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Tolazoline.]
[V04CA01, tolbutamide, Guanfacine may decrease the excretion rate of Tolbutamide which could result in a higher serum level.]
[M02AA21, tolmetin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Tolmetin.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of CNS depression can be increased when Guanfacine is combined with Tramadol.]
[N06AF04, tranylcypromine, Tranylcypromine may increase the hypotensive activities of Guanfacine.]
[N06AX05, trazodone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Trazodone.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Guanfacine.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Guanfacine.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Trichlormethiazide.]
[A03AB12, mepenzolate, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[A16AX12, trientine, Guanfacine may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Guanfacine is combined with Trifluperidol.]
[N05AA05, triflupromazine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.]
[N04AA01, trihexyphenidyl, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Trimebutine.]
[S01ED04, metipranolol, Guanfacine may increase the hypotensive activities of Metipranolol.]
[R06AD01, trimeprazine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of adverse effects can be increased when Trimethadione is combined with Guanfacine.]
[C02BA01, trimethaphan, Guanfacine may decrease the antihypertensive activities of Trimethaphan.]
[J01EA01, trimethoprim, Trimethoprim may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N06AA06, trimipramine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Trimipramine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Guanfacine.]
[A03BB01, butylscopolamine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[J01FA08, troleandomycin, The metabolism of Guanfacine can be decreased when combined with Troleandomycin.]
[N06AX24, vilazodone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Guanfacine.]
[C09CA09, azilsartan medoxomil, Guanfacine may decrease the antihypertensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tubocurarine.]
[R03DX07, roflumilast, Guanfacine may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Guanfacine may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[R02AA14, oxyquinoline, Guanfacine may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[A10BH05, linagliptin, The metabolism of Guanfacine can be decreased when combined with Linagliptin.]
[J05AP03, boceprevir, The metabolism of Guanfacine can be decreased when combined with Boceprevir.]
[J05AP02, telaprevir, The metabolism of Guanfacine can be decreased when combined with Telaprevir.]
[S01AA28, vancomycin, Guanfacine may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ezogabine.]
[B01AF01, rivaroxaban, Guanfacine may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, Indacaterol may decrease the antihypertensive activities of Guanfacine.]
[C08DA01, verapamil, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Verapamil.]
[N06AX09, viloxazine, The metabolism of Guanfacine can be decreased when combined with Viloxazine.]
[C04AX07, vincamine, Guanfacine may decrease the antihypertensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B01AA03, warfarin, Guanfacine may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Guanfacine.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Zuclopenthixol.]
[J05AE02, indinavir, The metabolism of Guanfacine can be decreased when combined with Indinavir.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Levetiracetam.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M05BA05, tiludronic acid, Guanfacine may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Guanfacine may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Guanfacine.]
[A02BC04, rabeprazole, Guanfacine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Guanfacine may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Guanfacine.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Guanfacine.]
[G04BD07, tolterodine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Guanfacine may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Atenolol.]
[L01FA01, rituximab, Guanfacine may increase the hypotensive activities of Rituximab.]
[J02AC03, voriconazole, The metabolism of Guanfacine can be decreased when combined with Voriconazole.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Guanfacine is combined with Atracurium.]
[S01FA01, atropine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Auranofin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[B03XA04, peginesatide, Guanfacine may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L04AX01, azathioprine, Azathioprine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[G04BE10, avanafil, The serum concentration of Avanafil can be increased when it is combined with Guanfacine.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Guanfacine.]
[A08AA11, lorcaserin, The risk or severity of adverse effects can be increased when Guanfacine is combined with Lorcaserin.]
[G04BD12, mirabegron, Mirabegron may decrease the antihypertensive activities of Guanfacine.]
[V03AX03, cobicistat, The metabolism of Guanfacine can be decreased when combined with Cobicistat.]
[J05AJ02, elvitegravir, The metabolism of Guanfacine can be decreased when combined with Elvitegravir.]
[L02BB04, enzalutamide, The metabolism of Guanfacine can be increased when combined with Enzalutamide.]
[C01CA18, octopamine, Octopamine may decrease the antihypertensive activities of Guanfacine.]
[L01EX05, regorafenib, Guanfacine may increase the bradycardic activities of Regorafenib.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Guanfacine.]
[D02BA02, octinoxate, Guanfacine may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[J05AE04, nelfinavir, The metabolism of Guanfacine can be decreased when combined with Nelfinavir.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Guanfacine.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Guanfacine.]
[C08CA13, lercanidipine, Guanfacine may decrease the antihypertensive activities of Lercanidipine.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Guanfacine is combined with Mosapride.]
[N06DA02, donepezil, The risk or severity of adverse effects can be increased when Donepezil is combined with Guanfacine.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[L04AA29, tofacitinib, Guanfacine may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Guanfacine.]
[R06AC06, thonzylamine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Guanfacine may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Guanfacine is combined with Diethyl ether.]
[H01CB05, pasireotide, Guanfacine may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, Sildenafil may increase the antihypertensive activities of Guanfacine.]
[V08CA11, gadofosveset, Guanfacine may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[A16AX08, teduglutide, Guanfacine may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, Guanfacine may increase the bradycardic activities of Bencyclane.]
[A10BH04, alogliptin, Guanfacine may decrease the excretion rate of Alogliptin which could result in a higher serum level.]
[A16AX09, glycerol phenylbutyrate, Guanfacine may decrease the excretion rate of Glycerol phenylbutyrate which could result in a higher serum level.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Pomalidomide.]
[N02BA10, benorilate, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Benorilate.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Guanfacine is combined with Benperidol.]
[A10BK02, canagliflozin, Canagliflozin may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Benzocaine.]
[L03AA12, ancestim, Guanfacine may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Celecoxib.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Guanfacine.]
[N04AC01, benztropine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[L01EC02, dabrafenib, The serum concentration of Guanfacine can be decreased when it is combined with Dabrafenib.]
[R02AX03, benzydamine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Benzydamine.]
[L01EE01, trametinib, Guanfacine may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Guanfacine is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Guanfacine may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Guanfacine is combined with Levomilnacipran.]
[C08EA02, bepridil, Guanfacine may decrease the antihypertensive activities of Bepridil.]
[C02KX05, riociguat, Guanfacine may decrease the antihypertensive activities of Riociguat.]
[A10BJ03, lixisenatide, Guanfacine may decrease the excretion rate of Lixisenatide which could result in a higher serum level.]
[C02KX04, macitentan, Guanfacine may decrease the antihypertensive activities of Macitentan.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Eslicarbazepine.]
[J05AP05, simeprevir, The metabolism of Guanfacine can be decreased when combined with Simeprevir.]
[J05AP08, sofosbuvir, Guanfacine may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vigabatrin.]
[A10BK01, dapagliflozin, Dapagliflozin may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[C01CA27, droxidopa, Droxidopa may decrease the antihypertensive activities of Guanfacine.]
[C07AB04, acebutolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tasimelteon.]
[A16AA07, metreleptin, The metabolism of Guanfacine can be increased when combined with Metreleptin.]
[L04AA32, apremilast, Guanfacine may decrease the excretion rate of Apremilast which could result in a higher serum level.]
[L02BG02, formestane, Guanfacine may decrease the excretion rate of Formestane which could result in a higher serum level.]
[S01ED02, betaxolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Betaxolol.]
[V03AB34, fomepizole, Guanfacine may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, Bethanidine may decrease the antihypertensive activities of Guanfacine.]
[L01ED02, ceritinib, Guanfacine may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Alfaxalone.]
[A10BK03, empagliflozin, The risk or severity of adverse effects can be increased when Guanfacine is combined with Empagliflozin.]
[R03AC19, olodaterol, Olodaterol may decrease the antihypertensive activities of Guanfacine.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[S01EE02, unoprostone, Guanfacine may increase the hypotensive activities of Unoprostone.]
[D11AA01, glycopyrronium, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05CM19, suvorexant, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AA04, acepromazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Acepromazine.]
[N04AA02, biperiden, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[S03AA06, gentamicin, Guanfacine may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[B01AF03, edoxaban, Guanfacine may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.]
[L01EF01, palbociclib, The risk or severity of adverse effects can be increased when Palbociclib is combined with Guanfacine.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[A03AA09, difemerine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[C01EB17, ivabradine, Guanfacine may increase the bradycardic activities of Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AX16, brexpiprazole, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Brexpiprazole.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Guanfacine is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cariprazine.]
[M02AA25, aceclofenac, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Aceclofenac.]
[M01AB11, acemetacin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Acemetacin.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Guanfacine.]
[N05AB07, acetophenazine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Acetophenazine.]
[V03AB37, idarucizumab, Guanfacine may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[J02AC05, isavuconazole, The metabolism of Guanfacine can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Guanfacine.]
[L01XG03, ixazomib, Guanfacine may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Guanfacine may decrease the antihypertensive activities of Selexipag.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Guanfacine.]
[M04AB05, lesinurad, Guanfacine may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Guanfacine is combined with Aprobarbital.]
[M01AE16, alminoprofen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Alminoprofen.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Brivaracetam.]
[L01XX52, venetoclax, The metabolism of Guanfacine can be decreased when combined with Venetoclax.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Bromazepam.]
[N04BC01, bromocriptine, Bromocriptine may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[A02AD05, aluminum magnesium silicate, Guanfacine may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine.]
[N06AA19, amineptin, The risk or severity of hypertension can be increased when Amineptine is combined with Guanfacine.]
[C08CA01, amlodipine, Guanfacine may decrease the antihypertensive activities of Amlodipine.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Aniracetam.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The risk or severity of adverse effects can be increased when Bupivacaine is combined with Guanfacine.]
[C07AA19, bupranolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Bupranolol.]
[N07BC01, buprenorphine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Guanfacine.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Rivastigmine may increase the bradycardic activities of Guanfacine.]
[M02AA03, clofezone, Guanfacine may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Guanfacine.]
[S01GX07, azelastine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01EF02, ribociclib, The metabolism of Guanfacine can be decreased when combined with Ribociclib.]
[A07EC04, balsalazide, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Balsalazide.]
[R03CC12, bambuterol, Bambuterol may decrease the antihypertensive activities of Guanfacine.]
[A06AH05, naldemedine, Guanfacine may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Guanfacine may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Guanfacine can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Beclamide.]
[C09AA07, benazepril, Guanfacine may decrease the antihypertensive activities of Benazepril.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Guanfacine.]
[P01CA02, benznidazole, Guanfacine may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[J01XX08, linezolid, Linezolid may increase the hypotensive activities of Guanfacine.]
[J05AF06, abacavir, Guanfacine may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Guanfacine can be decreased when combined with Tipranavir.]
[N07XX13, valbenazine, Guanfacine may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L01EX10, midostaurin, The metabolism of Guanfacine can be decreased when combined with Midostaurin.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Guanfacine.]
[J01MA23, delafloxacin, Guanfacine may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Acetylcholine.]
[L01BC06, capecitabine, Guanfacine may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[C07AB07, bisoprolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Bisoprolol.]
[R03AC17, bitolterol, Bitolterol may decrease the antihypertensive activities of Guanfacine.]
[J05AG03, efavirenz, The metabolism of Guanfacine can be decreased when combined with Efavirenz.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C07AA17, bopindolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Bopindolol.]
[N04AA11, bornaprine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Guanfacine is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Guanfacine may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Guanfacine.]
[M01AB07, bumadizone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Bumadizone.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Guanfacine is combined with Butobarbital.]
[N06AA15, butriptyline, The risk or severity of hypertension can be increased when Butriptyline is combined with Guanfacine.]
[A10BK04, ertugliflozin, Ertugliflozin may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vinylbital.]
[R06AX18, acrivastine, Guanfacine may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, Guanfacine may decrease the antihypertensive activities of Captopril.]
[L02BB05, apalutamide, The metabolism of Guanfacine can be increased when combined with Apalutamide.]
[N03AF01, carbamazepine, The metabolism of Guanfacine can be increased when combined with Carbamazepine.]
[A03AA03, camylofine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Guanfacine.]
[C07AG02, carvedilol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Carvedilol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Guanfacine.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Guanfacine.]
[L04AA37, baricitinib, Guanfacine may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01GB14, plazomicin, Guanfacine may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Celiprolol.]
[L01XX62, ivosidenib, The metabolism of Guanfacine can be increased when combined with Ivosidenib.]
[A16AX14, migalastat, Guanfacine may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Guanfacine can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The risk or severity of adverse effects can be increased when Dacomitinib is combined with Guanfacine.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Guanfacine.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Guanfacine is combined with Carbromal.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Guanfacine may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Lornoxicam.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Guanfacine.]
[R03BB08, revefenacin, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L01EX13, gilteritinib, The risk or severity of adverse effects can be increased when Gilteritinib is combined with Guanfacine.]
[A06AX05, prucalopride, Guanfacine may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, Guanfacine may decrease the antihypertensive activities of Cilazapril.]
[B01AC23, cilostazol, Guanfacine may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cinitapride.]
[S01ED05, carteolol, Carteolol may increase the hypotensive activities of Guanfacine.]
[N06AX27, esketamine, The risk or severity of hypertension can be increased when Esketamine is combined with Guanfacine.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Guanfacine.]
[J01FA09, clarithromycin, The metabolism of Guanfacine can be decreased when combined with Clarithromycin.]
[N06BA14, solriamfetol, The risk or severity of hypertension can be increased when Solriamfetol is combined with Guanfacine.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Brexanolone.]
[N05BA09, clobazam, The risk or severity of adverse effects can be increased when Clobazam is combined with Guanfacine.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cloxazolam.]
[C09CA06, candesartan, Guanfacine may decrease the antihypertensive activities of Candesartan.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AA06, cyamemazine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Guanfacine.]
[N07XX11, pitolisant, The serum concentration of Guanfacine can be decreased when it is combined with Pitolisant.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Yohimbine.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of adverse effects can be increased when Lasmiditan is combined with Guanfacine.]
[N03AX25, cenobamate, The serum concentration of Guanfacine can be decreased when it is combined with Cenobamate.]
[A16AX16, givosiran, Givosiran may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M09AX08, golodirsen, Guanfacine may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Guanfacine.]
[S01XA12, dexpanthenol, Guanfacine may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Guanfacine is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Lumateperone.]
[J05AE05, amprenavir, The metabolism of Guanfacine can be decreased when combined with Amprenavir.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Frovatriptan is combined with Guanfacine.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Guanfacine.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Dichloralphenazone.]
[R02AA03, dichlorobenzyl alcohol, Guanfacine may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Guanfacine may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Guanfacine is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Guanfacine.]
[M01AH02, rofecoxib, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Rofecoxib.]
[C08CA16, clevidipine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Clevidipine.]
[C01BD07, dronedarone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Dronedarone.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Guanfacine.]
[C02AA06, methoserpidine, Guanfacine may decrease the antihypertensive activities of Methoserpidine.]
[L01EH03, tucatinib, The metabolism of Tucatinib can be decreased when combined with Guanfacine.]
[A03AA08, dihexyverine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Opicapone.]
[C01CA14, dopexamine, Dopexamine may decrease the antihypertensive activities of Guanfacine.]
[G04BD09, trospium, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Droxicam.]
[V08CA05, mangafodipir, Guanfacine may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Guanfacine.]
[M02AA27, dexketoprofen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Dexketoprofen.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Guanfacine is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Guanfacine.]
[C08CA17, levamlodipine, Guanfacine may decrease the antihypertensive activities of Levamlodipine.]
[N05CD14, remimazolam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Remimazolam.]
[L04AC19, satralizumab, The serum concentration of Guanfacine can be decreased when it is combined with Satralizumab.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Guanfacine is combined with Oliceridine.]
[P01BA01, chloroquine, Chloroquine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Chlorpromazine.]
[A10BB02, chlorpropamide, Chlorpropamide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AF03, chlorprothixene, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Guanfacine.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Etifoxine.]
[N02BA07, ethenzamide, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Ethenzamide.]
[N02BA03, choline salicylate, The risk or severity of adverse effects can be increased when Guanfacine is combined with Choline salicylate.]
[N06BX18, vinpocetine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vinpocetine.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ethyl loflazepate.]
[M01AB08, etodolac, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Etodolac.]
[M02AA06, etofenamate, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Etofenamate.]
[B06AC06, berotralstat, The metabolism of Guanfacine can be decreased when combined with Berotralstat.]
[A16AX20, lonafarnib, The metabolism of Guanfacine can be decreased when combined with Lonafarnib.]
[M01AX25, chondroitin sulfates, Guanfacine may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Guanfacine.]
[P03AX07, abametapir, The serum concentration of Guanfacine can be increased when it is combined with Abametapir.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vericiguat.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Guanfacine is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Guanfacine.]
[M01AE05, fenbufen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Fenbufen.]
[C01CA19, fenoldopam, Guanfacine may decrease the antihypertensive activities of Fenoldopam.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Guanfacine.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Guanfacine.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02BG07, flupirtine, Guanfacine may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, Guanfacine may increase the sympathomimetic activities of Formoterol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Guanfacine.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Guanfacine is combined with Trichloroethylene.]
[H04AA02, dasiglucagon, Guanfacine may decrease the antihypertensive activities of Dasiglucagon.]
[A02BA01, cimetidine, The risk or severity of adverse effects can be increased when Cimetidine is combined with Guanfacine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Gabapentin is combined with Guanfacine.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N07CA02, cinnarizine, Cinnarizine may increase the bradycardic activities of Guanfacine.]
[L01XX73, sotorasib, The serum concentration of Guanfacine can be decreased when it is combined with Sotorasib.]
[S03AA07, ciprofloxacin, The metabolism of Guanfacine can be decreased when combined with Ciprofloxacin.]
[L01XA01, cisplatin, Guanfacine may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Guanfacine is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Guanfacine is combined with Fexinidazole.]
[V09AB03, ioflupane I-123, Guanfacine may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Guanfacine may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Guanfacine may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Guanfacine.]
[R03CC13, clenbuterol, Clenbuterol may decrease the antihypertensive activities of Guanfacine.]
[N06AX25, St. John's wort extract, The serum concentration of Guanfacine can be decreased when it is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Guanfacine.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Guanfacine.]
[L01EJ03, pacritinib, The serum concentration of Guanfacine can be increased when it is combined with Pacritinib.]
[N06AA04, clomipramine, The risk or severity of hypertension can be increased when Clomipramine is combined with Guanfacine.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Guanfacine.]
[C01EB24, mavacamten, The serum concentration of Guanfacine can be decreased when it is combined with Mavacamten.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Guanfacine.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Guanfacine.]
[N05AH02, clozapine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Clozapine.]
[J01GB12, arbekacin, Guanfacine may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Guanfacine.]
[H01AC08, somatrogon, The metabolism of Guanfacine can be increased when combined with Somatrogon.]
[S02DA02, cocaine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Guanfacine may increase the sedative activities of Metyrosine.]
[M01AX13, proquazone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Proquazone.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Guanfacine.]
[M03AC05, hexafluorenium, The risk or severity of adverse effects can be increased when Hexafluronium is combined with Guanfacine.]
[M04AC01, colchicine, Guanfacine may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Guanfacine may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Guanfacine is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ifenprodil.]
[A10BX03, nateglinide, Nateglinide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02BA16, imidazole-2-hydroxybenzoate, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Imidazole salicylate.]
[J01FA15, telithromycin, The metabolism of Guanfacine can be decreased when combined with Telithromycin.]
[B01AC10, indobufen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Indobufen.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Desloratadine is combined with Guanfacine.]
[J05AB14, valganciclovir, Guanfacine may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Guanfacine may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Guanfacine may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Guanfacine may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Guanfacine may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Guanfacine may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Valdecoxib.]
[A03AX10, isometheptene, Isometheptene may decrease the antihypertensive activities of Guanfacine.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Guanfacine.]
[M01AH04, parecoxib, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Parecoxib.]
[J02AC02, itraconazole, The metabolism of Guanfacine can be decreased when combined with Itraconazole.]
[S01AD03, acyclovir, The risk or severity of adverse effects can be increased when Acyclovir is combined with Guanfacine.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ketazolam.]
[M01AA06, kebuzone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Kebuzone.]
[L01EA01, imatinib, The risk or severity of adverse effects can be increased when Guanfacine is combined with Imatinib.]
[J02AC04, posaconazole, The metabolism of Guanfacine can be decreased when combined with Posaconazole.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Guanfacine.]
[S01EE03, bimatoprost, Bimatoprost may increase the hypotensive activities of Guanfacine.]
[C08CA09, lacidipine, Guanfacine may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Guanfacine can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Lonazolac.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Lormetazepam.]
[M02AA31, loxoprofen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Loxoprofen.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C09AA03, lisinopril, Guanfacine may decrease the antihypertensive activities of Lisinopril.]
[A06AD01, magnesium carbonate, Guanfacine may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, Guanfacine may decrease the antihypertensive activities of Manidipine.]
[A03AA04, mebeverine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Medifoxamine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Guanfacine.]
[C07AA14, mepindolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Mepindolol.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C01EB10, adenosine, The risk or severity of Tachycardia can be increased when Adenosine is combined with Guanfacine.]
[N04AA03, methixene, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, Guanfacine may increase the bradycardic activities of Cyclandelate.]
[R03CB02, methoxyphenamine, Methoxyphenamine may decrease the antihypertensive activities of Guanfacine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Guanfacine is combined with Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Cyclopenthiazide.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N06AX07, minaprine, Minaprine may increase the hypotensive activities of Guanfacine.]
[S01XA18, cyclosporine, The metabolism of Guanfacine can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Guanfacine.]
[R06AX02, cyproheptadine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Guanfacine may decrease the antihypertensive activities of Moexipril.]
[M02AA02, mofebutazone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Mofebutazone.]
[M01AX22, morniflumate, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Morniflumate.]
[C03XA02, conivaptan, The metabolism of Guanfacine can be decreased when combined with Conivaptan.]
[C02AC05, moxonidine, Guanfacine may decrease the antihypertensive activities of Moxonidine.]
[L01BC01, cytarabine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Cytarabine.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Guanfacine.]
[M01AH05, etoricoxib, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Etoricoxib.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[G03XA01, danazol, The metabolism of Guanfacine can be decreased when combined with Danazol.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Guanfacine is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Guanfacine is combined with Deanol.]
[C02CC04, debrisoquin, Guanfacine may decrease the antihypertensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[M01AX01, nabumetone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Nabumetone.]
[N07BB05, nalmefene, Guanfacine may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Nordazepam.]
[C07AB12, nebivolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Nebivolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N06AX06, nefazodone, The metabolism of Guanfacine can be decreased when combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Guanfacine.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Guanfacine.]
[C01CA23, theodrenaline, Theodrenaline may decrease the antihypertensive activities of Guanfacine.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Guanfacine.]
[C01CA05, norfenefrine, Norfenefrine may decrease the antihypertensive activities of Guanfacine.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of adverse effects can be increased when Guanfacine is combined with Escitalopram.]
[G04BD08, solifenacin, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Olsalazine.]
[N06AA01, desipramine, The risk or severity of hypertension can be increased when Desipramine is combined with Guanfacine.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Guanfacine.]
[V04CH02, indigo carmine, Guanfacine may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C09XA02, aliskiren, Guanfacine may decrease the antihypertensive activities of Aliskiren.]
[M01AE12, oxaprozin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Oxaprozin.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Guanfacine.]
[S03BA01, dexamethasone, The metabolism of Guanfacine can be increased when combined with Dexamethasone.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Oxiracetam.]
[N04AA08, dexetimide, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A03AA01, oxyphencyclimine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[N06BA02, dextroamphetamine, Amphetamine may decrease the antihypertensive activities of Guanfacine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Guanfacine.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Guanfacine.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Dextromoramide.]
[N06AB05, paroxetine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Paroxetine.]
[B01AC04, clopidogrel, The risk or severity of adverse effects can be increased when Clopidogrel is combined with Guanfacine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Guanfacine is combined with Diamorphine.]
[P03AC04, permethrin, Guanfacine may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Guanfacine.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Phenacemide.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Guanfacine.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Guanfacine.]
[N06AA08, dibenzepin, The risk or severity of hypertension can be increased when Dibenzepin is combined with Guanfacine.]
[S02DA04, dibucaine, The risk or severity of adverse effects can be increased when Cinchocaine is combined with Guanfacine.]
[R05DA08, pholcodine, Guanfacine may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Diclofenac.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[A03AA07, dicyclomine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C02DG01, pinacidil, Guanfacine may decrease the antihypertensive activities of Pinacidil.]
[A03AX04, pinaverium, Guanfacine may increase the bradycardic activities of Pinaverium.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Pipamperone.]
[A03AB14, pipenzolate, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[R03CC07, pirbuterol, Pirbuterol may decrease the antihypertensive activities of Guanfacine.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[A08AA03, diethylpropion, The risk or severity of adverse effects can be increased when Diethylpropion is combined with Guanfacine.]
[C08CA03, isradipine, The metabolism of Guanfacine can be decreased when combined with Isradipine.]
[D07XC04, diflucortolone, Guanfacine may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Diflunisal.]
[C01AA05, digoxin, Guanfacine may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Guanfacine may decrease the antihypertensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[N02CA01, dihydroergotamine, Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Guanfacine.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J05AE08, atazanavir, The metabolism of Guanfacine can be decreased when combined with Atazanavir.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Guanfacine.]
[H03BC01, potassium perchlorate, Guanfacine may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Pramocaine.]
[C08DB01, diltiazem, The metabolism of Guanfacine can be decreased when combined with Diltiazem.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Guanfacine.]
[V03AB09, dimercaprol, Guanfacine may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Guanfacine is combined with Pridinol.]
[R06AB03, dimethindene, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Procaterol may decrease the antihypertensive activities of Guanfacine.]
[M02AX03, dimethyl sulfoxide, Guanfacine may decrease the excretion rate of Dimethyl sulfoxide which could result in a higher serum level.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Guanfacine.]
[N02BB04, propyphenazone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Propyphenazone.]
[M01AB14, proglumetacin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Proglumetacin.]
[G02AD02, dinoprostone, The risk or severity of adverse effects can be increased when Dinoprostone is combined with Guanfacine.]
[R06AA02, diphenhydramine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Guanfacine is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Quazepam.]
[C09AA06, quinapril, Guanfacine may decrease the antihypertensive activities of Quinapril.]
[B01AC07, dipyridamole, Dipyridamole may increase the antihypertensive activities of Guanfacine.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Guanfacine.]
[N06AA23, quinupramine, The risk or severity of hypertension can be increased when Quinupramine is combined with Guanfacine.]
[A03FA02, cisapride, The risk or severity of adverse effects can be increased when Cisapride is combined with Guanfacine.]
[C09AA05, ramipril, Guanfacine may decrease the antihypertensive activities of Ramipril.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Guanfacine.]
[R03CC14, reproterol, Reproterol may decrease the antihypertensive activities of Guanfacine.]
[S01AX06, resorcinol, Guanfacine may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Disopyramide.]
[S02AA12, rifamycin SV, The metabolism of Guanfacine can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Guanfacine can be increased when combined with Rifapentine.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Guanfacine.]
[N05AX08, risperidone, Guanfacine may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Guanfacine.]
[A04AD12, aprepitant, The metabolism of Guanfacine can be decreased when combined with Aprepitant.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[G04BE08, tadalafil, Guanfacine may decrease the antihypertensive activities of Tadalafil.]
[S01BC05, ketorolac, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Ketorolac.]
[C02KX02, ambrisentan, Guanfacine may decrease the antihypertensive activities of Ambrisentan.]
[C01EB18, ranolazine, Ranolazine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02BA06, salsalate, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Salsalate.]
[R03AC12, salmeterol, The risk or severity of adverse effects can be increased when Salmeterol is combined with Guanfacine.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C01CA07, dobutamine, Dobutamine may decrease the antihypertensive activities of Guanfacine.]
[C01CA04, dopamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Dopamine.]
[N06AA16, dothiepin, The risk or severity of hypertension can be increased when Dosulepin is combined with Guanfacine.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Guanfacine.]
[N06AA12, doxepin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Doxepin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Guanfacine is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Guanfacine is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Sibutramine.]
[A12CA02, sodium sulfate, Guanfacine may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Guanfacine may decrease the antihypertensive activities of Spirapril.]
[R03DA01, dyphylline, Dyphylline may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Guanfacine is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Guanfacine.]
[V04CX07, edrophonium, Edrophonium may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C07AB13, talinolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Talinolol.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M01AC02, tenoxicam, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Tenoxicam.]
[G04CA03, terazosin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Terazosin.]
[G04BD05, terodiline, Guanfacine may increase the bradycardic activities of Terodiline.]
[C07AA16, tertatolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Tertatolol.]
[S01GA02, tetrahydrozoline, Tetryzoline may decrease the antihypertensive activities of Guanfacine.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Guanfacine is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Guanfacine is combined with Thiopropazate.]
[G04BD01, emepronium, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of hypertension can be increased when Tianeptine is combined with Guanfacine.]
[C09AA02, enalapril, Guanfacine may decrease the antihypertensive activities of Enalapril.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Tofisopam.]
[M01AG02, tolfenamic acid, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Tolfenamic acid.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Guanfacine.]
[N06BA09, atomoxetine, Atomoxetine may decrease the antihypertensive activities of Guanfacine.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Guanfacine.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Guanfacine.]
[C09AA10, trandolapril, Guanfacine may decrease the antihypertensive activities of Trandolapril.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Guanfacine is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Guanfacine is combined with Triclofos.]
[A03AB08, tridihexethyl, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Guanfacine.]
[N04AA12, tropatepine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, Tulobuterol may decrease the antihypertensive activities of Guanfacine.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Guanfacine.]
[C02CA06, urapidil, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Guanfacine is combined with Veralipride.]
[S01FB02, ephedrine, Ephedrine may decrease the antihypertensive activities of Guanfacine.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Guanfacine.]
[N06AX16, venlafaxine, Venlafaxine may increase the tachycardic activities of Guanfacine.]
[C01CX07, xamoterol, Xamoterol may decrease the antihypertensive activities of Guanfacine.]
[S01GA03, xylometazoline, Xylometazoline may decrease the antihypertensive activities of Guanfacine.]
[C08CA12, mepirodipine, Guanfacine may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Epinephrine.]
[C09AA15, zofenopril, Guanfacine may decrease the antihypertensive activities of Zofenopril.]
[N05CF02, zolpidem, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Zomepirac.]
[N03AX15, zonisamide, The risk or severity of adverse effects can be increased when Zonisamide is combined with Guanfacine.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Guanfacine can be decreased when combined with Fusidic acid.]
[N07XX04, sodium oxybate, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M01AG01, mefenamic acid, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Mefenamic acid.]
[C01DA05, pentaerythritol tetranitrate, Guanfacine may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Guanfacine.]
[C01BG01, moricizine, The risk or severity of adverse effects can be increased when Moricizine is combined with Guanfacine.]
[G02AB03, ergonovine, Ergometrine may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[C04AE01, ergoloid mesylates, USP, Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[N02CA02, ergotamine, The metabolism of Guanfacine can be decreased when combined with Ergotamine.]
[L03AX05, pidotimod, Guanfacine may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[S01AA17, erythromycin, The metabolism of Guanfacine can be decreased when combined with Erythromycin.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Estazolam.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C01CA15, gepefrine, Gepefrine may decrease the antihypertensive activities of Guanfacine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Guanfacine.]
[V03AF05, amifostine, Guanfacine may increase the hypotensive activities of Amifostine.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N04AA05, profenamine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Profenamine.]
[N03AD01, ethosuximide, The risk or severity of adverse effects can be increased when Ethosuximide is combined with Guanfacine.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Guanfacine.]
[M01AC06, meloxicam, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Meloxicam.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ethylmorphine.]
[C01CA01, etilefrine, Etilefrine may decrease the antihypertensive activities of Guanfacine.]
[N01AX07, etomidate, The risk or severity of adverse effects can be increased when Etomidate is combined with Guanfacine.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Guanfacine is combined with Sertindole.]
[L04AD02, tacrolimus, Tacrolimus may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[R06AX12, terfenadine, The metabolism of Guanfacine can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Guanfacine may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The risk or severity of adverse effects can be increased when Guanfacine is combined with Bupropion.]
[N06AB08, fluvoxamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Fluvoxamine.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Guanfacine may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Guanfacine may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C08CA02, felodipine, Guanfacine may decrease the antihypertensive activities of Felodipine.]
[C08EA01, fendiline, Guanfacine may increase the bradycardic activities of Fendiline.]
[N03AX26, fenfluramine, The risk or severity of adverse effects can be increased when Fenfluramine is combined with Guanfacine.]
[M01AE04, fenoprofen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Fenoprofen.]
[R03CC04, fenoterol, Fenoterol may decrease the antihypertensive activities of Guanfacine.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Guanfacine.]
[R03CC02, albuterol, Salbutamol may decrease the antihypertensive activities of Guanfacine.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Guanfacine.]
[N07AX03, cevimeline, Cevimeline may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[G04BD02, flavoxate, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[N02BG04, floctafenine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Floctafenine.]
[J02AC01, fluconazole, The metabolism of Guanfacine can be decreased when combined with Fluconazole.]
[J02AX01, flucytosine, Guanfacine may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Guanfacine may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Flunarizine.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of hypertension can be increased when Melitracen is combined with Guanfacine.]
[V03AZ01, ethanol, Ethanol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N06AB03, fluoxetine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Fluoxetine.]
[N05AF01, flupenthixol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Flupentixol.]
[N05AB02, fluphenazine, The risk or severity of adverse effects can be increased when Fluphenazine is combined with Guanfacine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Guanfacine.]
[S01BC04, flurbiprofen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Flurbiprofen.]
[N05AG01, fluspirilene, The risk or severity of adverse effects can be increased when Guanfacine is combined with Fluspirilene.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L01BC03, tegafur, Guanfacine may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, Adrafinil may decrease the antihypertensive activities of Guanfacine.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Guanfacine is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Guanfacine.]
[J05AE10, darunavir, The metabolism of Guanfacine can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Guanfacine is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Guanfacine is combined with Amisulpride.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Guanfacine.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Gallamine.]
[C08DA02, gallopamil, Guanfacine may increase the bradycardic activities of Gallopamil.]
[S01AD09, ganciclovir, The risk or severity of adverse effects can be increased when Ganciclovir is combined with Guanfacine.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Guanfacine.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Guanfacine is combined with Bifemelane.]
[C10AB04, gemfibrozil, Guanfacine may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Guanfacine may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, Cabergoline may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[N03AD03, methsuximide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Guanfacine.]
[A10BB07, glipizide, Guanfacine may decrease the excretion rate of Glipizide which could result in a higher serum level.]
[N05CM18, dexmedetomidine, The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Guanfacine.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Glutethimide.]
[C05AE01, nitroglycerin, Guanfacine may decrease the antihypertensive activities of Nitroglycerin.]
[C02CA04, doxazosin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Doxazosin.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C07AB09, esmolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Esmolol.]
[M01CB04, aurothioglucose, Guanfacine may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Guanfacine may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[C09AA09, fosinopril, Guanfacine may decrease the antihypertensive activities of Fosinopril.]
[S01EX01, guanethidine, Guanfacine may decrease the antihypertensive activities of Guanethidine.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Guanfacine.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Guanfacine is combined with Halothane.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Guanfacine.]
[N06BX13, idebenone, Guanfacine may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Guanfacine is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Guanfacine is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C09CA01, losartan, Guanfacine may decrease the antihypertensive activities of Losartan.]
[G03DC01, allylestrenol, Guanfacine may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Mesalazine.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Guanfacine.]
[R03CC05, hexoprenaline, Hexoprenaline may decrease the antihypertensive activities of Guanfacine.]
[J05AG01, nevirapine, The risk or severity of adverse effects can be increased when Nevirapine is combined with Guanfacine.]
[C08CA10, nilvadipine, The metabolism of Guanfacine can be decreased when combined with Nilvadipine.]
[M02AA26, nimesulide, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Nimesulide.]
[C09AA04, perindopril, Guanfacine may decrease the antihypertensive activities of Perindopril.]
[C02DB02, hydralazine, Guanfacine may decrease the antihypertensive activities of Hydralazine.]
[C03AA03, hydrochlorothiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Hydrochlorothiazide.]
[R05DA03, hydrocodone, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Guanfacine may decrease the excretion rate of Potassium acetate which could result in a higher serum level.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[G04BD06, propiverine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Propiverine.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Guanfacine is combined with Prothipendyl.]
[B05AA07, hetastarch, Guanfacine may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[C02AC06, rilmenidine, Guanfacine may decrease the antihypertensive activities of Rilmenidine.]
[R02AX02, ibuprofen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Ibuprofen.]
[B05XA08, sodium acetate, Guanfacine may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01AA06, ifosfamide, Guanfacine may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Guanfacine.]
[N06AA02, imipramine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Guanfacine is combined with Paclitaxel.]
[R01AD07, tixocortol, Guanfacine may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The risk or severity of adverse effects can be increased when Tizanidine is combined with Guanfacine.]
[L01CE01, topotecan, Guanfacine may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Guanfacine.]
[S01BC01, indomethacin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Indomethacin.]
[C02CA02, indoramin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Indoramin.]
[A11HA07, inositol, Guanfacine may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Guanfacine is combined with Milnacipran.]
[A03AA30, piperidolate, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, Guanfacine may decrease the excretion rate of Varenicline which could result in a higher serum level.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Articaine.]
[A10BH01, sitagliptin, Guanfacine may decrease the excretion rate of Sitagliptin which could result in a higher serum level.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Guanfacine.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Ramelteon is combined with Guanfacine.]
[R06AE01, buclizine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[L01XX35, anagrelide, The risk or severity of Tachycardia can be increased when Anagrelide is combined with Guanfacine.]
[C07AA01, alprenolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Alprenolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Guanfacine may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of hypertension can be increased when Iprindole is combined with Guanfacine.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Guanfacine.]
[N05AA07, chlorproethazine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Guanfacine.]
[S01EC03, dorzolamide, Dorzolamide may increase the hypotensive activities of Guanfacine.]
[R03CC06, isoetharine, Isoetharine may decrease the antihypertensive activities of Guanfacine.]
[C09AA16, imidapril, Guanfacine may decrease the antihypertensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Guanfacine.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Guanfacine.]
[J04AC01, isoniazid, The metabolism of Guanfacine can be decreased when combined with Isoniazid.]
[J05AX05, inosine pranobex, Guanfacine may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Isoprenaline may decrease the antihypertensive activities of Guanfacine.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Guanfacine.]
[D10BA01, isotretinoin, Isotretinoin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C04AA01, isoxsuprine, Isoxsuprine may decrease the antihypertensive activities of Guanfacine.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Guanfacine.]
[S01AA24, kanamycin, Guanfacine may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[N01AX03, ketamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ketamine.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ketanserin.]
[B01AC22, prasugrel, Guanfacine may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Guanfacine can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Olanzapine.]
[M02AA10, ketoprofen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Ketoprofen.]
[C01CA22, arbutamine, Arbutamine may decrease the antihypertensive activities of Guanfacine.]
[N04BC09, rotigotine, Guanfacine may increase the sedative activities of Rotigotine.]
[C07AG01, labetalol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Labetalol.]
[N04BB01, amantadine, The risk or severity of adverse effects can be increased when Amantadine is combined with Guanfacine.]
[C02AA05, deserpidine, Guanfacine may decrease the antihypertensive activities of Deserpidine.]
[A06AX03, lubiprostone, Guanfacine may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Guanfacine is combined with Levodopa.]
[S02DA01, lidocaine, The risk or severity of adverse effects can be increased when Lidocaine is combined with Guanfacine.]
[C08EX01, lidoflazine, Guanfacine may increase the bradycardic activities of Lidoflazine.]
[S01AA21, amikacin, Guanfacine may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Lisuride may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[N06AA07, lofepramine, The risk or severity of hypertension can be increased when Lofepramine is combined with Guanfacine.]
[A07DA03, loperamide, Loperamide may increase the bradycardic activities of Guanfacine.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Guanfacine.]
[C10AA02, lovastatin, The metabolism of Guanfacine can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Guanfacine.]
[B05XA11, magnesium chloride, Guanfacine may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Guanfacine may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Guanfacine can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Guanfacine may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[L01EA03, nilotinib, The metabolism of Guanfacine can be decreased when combined with Nilotinib.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Guanfacine.]
[C02BB01, mecamylamine, Guanfacine may decrease the antihypertensive activities of Mecamylamine.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Guanfacine.]
[M02AA18, meclofenamic acid, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Meclofenamic acid.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Medazepam.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Guanfacine is combined with Melatonin.]
[N06DX01, memantine, Guanfacine may decrease the excretion rate of Memantine which could result in a higher serum level.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Guanfacine.]
[C01CA11, mephentermine, Mephentermine may decrease the antihypertensive activities of Guanfacine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Guanfacine.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Guanfacine.]
[N01BB03, mepivacaine, The risk or severity of adverse effects can be increased when Mepivacaine is combined with Guanfacine.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Guanfacine.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Guanfacine is combined with Meptazinol.]
[G04BX16, tiopronin, Guanfacine may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The risk or severity of adverse effects can be increased when Mesoridazine is combined with Guanfacine.]
[N05AX13, paliperidone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Paliperidone.]
[C01CA09, metaraminol, Metaraminol may decrease the antihypertensive activities of Guanfacine.]
[A10BA02, metformin, Metformin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Guanfacine.]
[H01CB03, lanreotide, Guanfacine may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Guanfacine.]
[N06BA03, methamphetamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Metamfetamine.]
[A03AB07, methantheline, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Guanfacine is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Methaqualone.]
[J05AF05, lamivudine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Lamivudine.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Guanfacine.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Metergoline may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[H03BB02, methimazole, The metabolism of Guanfacine can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Guanfacine may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Guanfacine.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Guanfacine.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Ziconotide.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, Methoxamine may decrease the antihypertensive activities of Guanfacine.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Guanfacine is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, Guanfacine may decrease the antihypertensive activities of Methyldopa.]
[V04CG05, methylene blue, Methylene blue may increase the hypotensive activities of Guanfacine.]
[G02AB01, methylergonovine, Methylergometrine may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Guanfacine.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Guanfacine.]
[G03EK01, methyltestosterone, Guanfacine may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Guanfacine is combined with Methyprylon.]
[N02CA04, methysergide, Methysergide may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Guanfacine.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Guanfacine which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Metoprolol.]
[V04CD01, metyrapone, Metyrapone may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N06AX03, mianserin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Mianserin.]
[S02AA13, miconazole, The metabolism of Guanfacine can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Aminophenazone.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Guanfacine.]
[C01CA17, midodrine, Midodrine may decrease the antihypertensive activities of Guanfacine.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C09CA03, valsartan, Guanfacine may decrease the antihypertensive activities of Valsartan.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[D11AX01, minoxidil, Guanfacine may decrease the antihypertensive activities of Minoxidil.]
[L01XX23, mitotane, The metabolism of Guanfacine can be increased when combined with Mitotane.]
[N06BA12, lisdexamfetamine, Lisdexamfetamine may decrease the antihypertensive activities of Guanfacine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Molindone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Guanfacine.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Guanfacine.]
[C01BD01, amiodarone, The metabolism of Guanfacine can be decreased when combined with Amiodarone.]
[N06AA09, amitriptyline, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Amitriptyline.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Guanfacine.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Guanfacine.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L04AB05, certolizumab pegol, Guanfacine may decrease the excretion rate of Certolizumab pegol which could result in a higher serum level.]
[G04BA01, ammonium chloride, Guanfacine may decrease the excretion rate of Ammonium chloride which could result in a higher serum level.]
[L04AA06, mycophenolic acid, Guanfacine may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Guanfacine.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Guanfacine is combined with Silodosin.]
[N06AA17, amoxapine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Amoxapine.]
[N03AB05, fosphenytoin, The metabolism of Guanfacine can be increased when combined with Fosphenytoin.]
[C07AA12, nadolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Nadolol.]
[J01CA04, amoxicillin, Guanfacine may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, Guanfacine may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Guanfacine is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Guanfacine.]
[V03AB15, naloxone, The metabolism of Guanfacine can be decreased when combined with Naloxone.]
[S01GA01, naphazoline, Naphazoline may decrease the antihypertensive activities of Guanfacine.]
[N06BA01, amphetamine, Amphetamine may decrease the antihypertensive activities of Guanfacine.]
[M02AA12, naproxen, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Naproxen.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Guanfacine is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Guanfacine.]
[S03AA01, neomycin, Guanfacine may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Guanfacine.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Guanfacine.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05AX14, iloperidone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Guanfacine.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[L03AX16, plerixafor, Guanfacine may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Guanfacine may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Guanfacine may decrease the antihypertensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C01CE01, inamrinone, Guanfacine may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Guanfacine.]
[C08CA04, nicardipine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Nicardipine.]
[C04AE02, nicergoline, Nicergoline may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Nicotine is combined with Guanfacine.]
[C08CA05, nifedipine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Nifedipine.]
[M02AA17, niflumic acid, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Niflumic acid.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Guanfacine is combined with Amyl Nitrite.]
[C08CA06, nimodipine, Guanfacine may decrease the antihypertensive activities of Nimodipine.]
[C08CA07, nisoldipine, Guanfacine may decrease the antihypertensive activities of Nisoldipine.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Nitrazepam.]
[C08CA08, nitrendipine, Guanfacine may decrease the antihypertensive activities of Nitrendipine.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Guanfacine.]
[J01XE01, nitrofurantoin, Nitrofurantoin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Zaleplon is combined with Guanfacine.]
[N04BC05, pramipexole, Guanfacine may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Guanfacine may decrease the antihypertensive activities of Nitroprusside.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Nomifensine.]
[C01CA03, norepinephrine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Norepinephrine.]
[C02KX01, bosentan, Guanfacine may decrease the antihypertensive activities of Bosentan.]
[N06AA10, nortriptyline, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Nortriptyline.]
[G02CA02, nylidrin, Nylidrin may decrease the antihypertensive activities of Guanfacine.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Guanfacine.]
[N06AA05, opipramol, The risk or severity of hypertension can be increased when Opipramol is combined with Guanfacine.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Guanfacine is combined with Opium.]
[R03CB03, metaproterenol, Orciprenaline may decrease the antihypertensive activities of Guanfacine.]
[G04CA02, tamsulosin, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Tamsulosin.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Guanfacine.]
[C07AA02, oxprenolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Guanfacine.]
[C01DX03, oxyfedrine, Oxyfedrine may decrease the antihypertensive activities of Guanfacine.]
[S01GA04, oxymetazoline, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Guanfacine is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Oxyphenbutazone.]
[A03AB03, oxyphenonium, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Asenapine.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.]
[M03AC01, pancuronium, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Pancuronium.]
[J04AB30, capreomycin, Guanfacine may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Papaverine.]
[N05CC05, paraldehyde, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Guanfacine.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[G04BD11, fesoterodine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of adverse effects can be increased when Guanfacine is combined with Penfluridol.]
[J01CE09, penicillin G procaine, Guanfacine may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Guanfacine.]
[N05CA01, pentobarbital, The metabolism of Guanfacine can be increased when combined with Pentobarbital.]
[L01XX08, pentostatin, Guanfacine may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Guanfacine.]
[N05AB10, perazine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Perazine.]
[N04BC02, pergolide, Pergolide may increase the hypertensive and vasoconstricting activities of Guanfacine.]
[C08EX02, perhexiline, Guanfacine may increase the bradycardic activities of Perhexiline.]
[N05AB03, perphenazine, The risk or severity of adverse effects can be increased when Perphenazine is combined with Guanfacine.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Guanfacine.]
[A10BA01, phenformin, The risk or severity of adverse effects can be increased when Phenformin is combined with Guanfacine.]
[N03AA02, phenobarbital, The metabolism of Guanfacine can be increased when combined with Phenobarbital.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Phenoxybenzamine.]
[A08AA01, phentermine, Phentermine may decrease the antihypertensive activities of Guanfacine.]
[V03AB36, phentolamine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Phentolamine.]
[M02AA01, phenylbutazone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Phenylbutazone.]
[S01GA05, phenylephrine, Phenylephrine may decrease the antihypertensive activities of Guanfacine.]
[R01BA01, phenylpropanolamine, Phenylpropanolamine may decrease the antihypertensive activities of Guanfacine.]
[N03AB02, phenytoin, The metabolism of Guanfacine can be increased when combined with Phenytoin.]
[S01AE05, levofloxacin, Guanfacine may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[B02BA01, vitamin K1, Guanfacine may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C08CX01, mibefradil, Guanfacine may decrease the antihypertensive activities of Mibefradil.]
[N05AG02, pimozide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Pimozide.]
[C07AA03, pindolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Pindolol.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Guanfacine can be decreased when combined with Saquinavir.]
[N05AC04, pipothiazine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Pipotiazine.]
[N06BX03, piracetam, Guanfacine may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Guanfacine may decrease the antihypertensive activities of Eprosartan.]
[A02BX03, pirenzepine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Guanfacine is combined with Piritramide.]
[S01BC06, piroxicam, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Piroxicam.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[N02CX01, pizotyline, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Pizotifen.]
[J05AG02, delavirdine, The metabolism of Guanfacine can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Guanfacine may decrease the antihypertensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Guanfacine is combined with Proxibarbal.]
[A10BG02, rosiglitazone, Rosiglitazone may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Alosetron is combined with Guanfacine.]
[C03AA05, polythiazide, The therapeutic efficacy of Guanfacine can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Guanfacine can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, Guanfacine may decrease the excretion rate of Saxagliptin which could result in a higher serum level.]
[B05XA01, potassium chloride, Potassium chloride may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C07AB01, practolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Guanfacine is combined with Prazepam.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Guanfacine.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[C01DX02, prenylamine, Guanfacine may increase the bradycardic activities of Prenylamine.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Guanfacine.]
[P01BA03, primaquine, The metabolism of Guanfacine can be decreased when combined with Primaquine.]
[N03AA03, primidone, The metabolism of Guanfacine can be increased when combined with Primidone.]
[M04AB01, probenecid, The risk or severity of adverse effects can be increased when Probenecid is combined with Guanfacine.]
[C01BA02, procainamide, Guanfacine may decrease the excretion rate of Procainamide which could result in a higher serum level.]
[S01HA05, procaine, Procaine may increase the hypotensive activities of Guanfacine.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Guanfacine.]
[C10AB05, fenofibrate, Guanfacine may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Guanfacine.]
[N04AA04, procyclidine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The risk or severity of adverse effects can be increased when Progesterone is combined with Guanfacine.]
[N05AA03, promazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Promazine.]
[R06AD02, promethazine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.]
[C01BC03, propafenone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Propafenone.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Guanfacine is combined with Propanidid.]
[A03AB05, propantheline, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Periciazine.]
[N05CM06, propiomazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Guanfacine.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Guanfacine.]
[C07AA05, propranolol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Propranolol.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Guanfacine.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Guanfacine.]
[N06AA11, protriptyline, The risk or severity of hypertension can be increased when Protriptyline is combined with Guanfacine.]
[R01BA02, pseudoephedrine, Pseudoephedrine may decrease the antihypertensive activities of Guanfacine.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Guanfacine.]
[N07XX07, dalfampridine, Guanfacine may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Guanfacine.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Guanfacine is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Guanfacine is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Guanfacine is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Guanfacine is combined with Mepyramine.]
[C01BA01, quinidine, Guanfacine may decrease the excretion rate of Quinidine which could result in a higher serum level.]
[P01BC01, quinine, The risk or severity of adverse effects can be increased when Quinine is combined with Guanfacine.]
[A02BA02, ranitidine, The risk or severity of adverse effects can be increased when Ranitidine is combined with Guanfacine.]
[C02AA01, rescinnamine, Guanfacine may decrease the antihypertensive activities of Rescinnamine.]
[C02AA02, reserpine, The risk or severity of adverse effects can be increased when Reserpine is combined with Guanfacine.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Guanfacine can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, Rimiterol may decrease the antihypertensive activities of Guanfacine.]
[G02CA01, ritodrine, Ritodrine may decrease the antihypertensive activities of Guanfacine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Guanfacine is combined with Oxitriptan.]
[N02BA05, salicylamide, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Salicylamide.]
[A07EC01, sulfasalazine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Sulfasalazine.]
[S01BC08, salicylic acid, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Salicylic acid.]
[S01FA02, scopolamine, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Guanfacine.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Guanfacine.]
[L01FA03, obinutuzumab, Guanfacine may increase the hypotensive activities of Obinutuzumab.]
[J01GB08, sisomicin, Guanfacine may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Guanfacine may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Guanfacine may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Sotalol.]
[C03DA01, spironolactone, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Spironolactone.]
[N03AG01, valproic acid, The serum concentration of Valproic acid can be increased when it is combined with Guanfacine.]
[C01DA14, isosorbide mononitrate, The risk or severity of adverse effects can be increased when Guanfacine is combined with Isosorbide mononitrate.]
[H02CA04, levoketoconazole, The metabolism of Guanfacine can be decreased when combined with Levoketoconazole.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Guanfacine which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Tiaprofenic acid.]
[R03BB01, ipratropium bromide, Guanfacine may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
